News 19.10.2023 The CUTISS team is proud to announce the recent inauguration of CUTISS Innovation, the French subsidiary of CUTISS AG, at the renowned Sophia Antipolis technology park in France. CUTISS Innovation is supporting and extending our R&D activities in regenerative medicine, including skin pigmentation, aging and healing. The Provence-Alpes-Côte d’Azur region is...
News 18.10.2023 Zurich, Switzerland – October 17, 2023 InSphero AG, a global leader in 3D in vitro technologies, is thrilled to announce the launch of its brand-new website, designed to provide researchers with enhanced usability and an array of resources for cutting-edge advancements in Liver Safety, Liver Disease, Oncology & Immunology, and Islet Biology. The website...
News 16.10.2023 Zurich, Switzerland - 12.10.2023 Neurimmune announced today that preclinical data relating to its human antibody NI203 targeting pathologic aggregates of the beta cell peptide hormone islet amyloid polypeptide (IAPP) have been published in the current issue of Nature Communications. The paper “A human antibody against pathologic IAPP aggregates protects beta cells in...
News 14.10.2023 Schlieren (Zurich), Switzerland, October 12, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next-generation bone graft technologies, today provides an update on its commercial activities for the first nine months of 2023 and announces changes and a transition in responsibilities within the Executive Management. Direct sales of MagnetOs rose...
News 14.10.2023 Schlieren (Zurich), October 9, 2023 - LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform...